Here is what the suboxone doctor had to say.. Keep in mind, he is an anesthesiologist as well.
I will get to the bluelight post when I have a chance later today. I really need to learn more about the basic science of bupe at the receptor level-- unfortunately the chemical is 30 years old and generic, so there is not a great deal of interest in studying the chemical itself. Maybe that will change... but I came across a paper a couple years ago that showed that at the mu receptor, buprenorphine is an agonist up to a certain point, and then it hits a ceiling-- but at very high doses it actually starts to antagonize itself. At the receptor, we are talking about molecules that are attaching and releasing very
quickly-- there are 'association constants' and 'dissociation constants'
that determine the overall degree of binding at the receptor. The agonism/antagonism is a different issue, and relates to the changes in shape of the receptor site that occur when bound vs when not bound with drug. To have mixed properties, you need to imagine the receptor site as having several different binding configurations; one configuration is favored when bupe is in low concentrations (the 'agonist'
configuration') and another when in high concentrations (the 'ceiling
configuration') and maybe a third where in super high concentrations, but bupe will bind to a lower-affinity configuration that shapes the receptor in a way where it acts as if nothing is bound to it, and nothing CAN bind to it-- the 'antagonist configuration'. This is all guesswork on my part based on how other receptors work in general-- I don't know if anyone has defined these specific properties to the mu receptor and buprenorphine.
I will get to the bluelight post when I have a chance later today. I really need to learn more about the basic science of bupe at the receptor level-- unfortunately the chemical is 30 years old and generic, so there is not a great deal of interest in studying the chemical itself. Maybe that will change... but I came across a paper a couple years ago that showed that at the mu receptor, buprenorphine is an agonist up to a certain point, and then it hits a ceiling-- but at very high doses it actually starts to antagonize itself. At the receptor, we are talking about molecules that are attaching and releasing very
quickly-- there are 'association constants' and 'dissociation constants'
that determine the overall degree of binding at the receptor. The agonism/antagonism is a different issue, and relates to the changes in shape of the receptor site that occur when bound vs when not bound with drug. To have mixed properties, you need to imagine the receptor site as having several different binding configurations; one configuration is favored when bupe is in low concentrations (the 'agonist'
configuration') and another when in high concentrations (the 'ceiling
configuration') and maybe a third where in super high concentrations, but bupe will bind to a lower-affinity configuration that shapes the receptor in a way where it acts as if nothing is bound to it, and nothing CAN bind to it-- the 'antagonist configuration'. This is all guesswork on my part based on how other receptors work in general-- I don't know if anyone has defined these specific properties to the mu receptor and buprenorphine.